foto london banner.jpg

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

8 Things we learned from Orphan Drugs Industry Adv...

Christian Girard, expert in orphan drugs, competitive intelligence, in/out ...

Read More

ISSUE 9, 2016 Drugs & Dealers Magazine Released

Biotech and Money are pleased to announce the release of the latest Drugs &...

Read More

Discovering new therapies to treat myocardial infa...

We recently spoke to Eddy Littler of Domainex about discovering new therapi...

Read More

Creating a substantial franchise in the allergy se...

We recently spoke to Manuel Llobet of Allergy Therapeutics about franchisin...

Read More

ISSUE 8, 2016 Drugs & Dealers Magazine Released

Biotech and Money are pleased to announce the release of the latest Drugs &...

Read More

ADVANCED THERAPIES: NO LONGER JUST HYPE?

10-12 years ago everyone was talking about cell therapy and regenerative me...

Read More

6 things we learned from Manuel llobet, CEO of All...

Biotech and Money recently had the opportunity to speak to Manuel Llobet, C...

Read More

4 things I learned from Eddy Littler, CEO of Domai...

Biotech and Money recently had the opportunity to catch up with Eddy Little...

Read More

Announcing Brand New Agenda for 2nd Annual Biotech...

What do the Global BD heads of GSK, AstraZeneca, rockstar investors like Si...

Read More

Transformational deal making: Oxford Biomedica

Given the recent announcement of Oxford Biomedica securing £50m loan fundin...

Read More

Spotting baby biotech unicorns

Valuing biotech assets, whether an early-stage private investment in a prec...

Read More

Five things I learned from Misti Ushio, Managing D...

Having previously worked as a researcher for Merck and at Columbia Universi...

Read More

Add Your Response